The use of adjuvant chemotherapy is not associated with recurrence or cancer-specific death following curative resection for stage III rectal cancer: a competing risks analysis

Table 3 Association between adjuvant chemotherapy (AC) and recurrence of rectal cancer and between other variables independently associated with administration of AC and recurrence, after adjustment for the competing risk of death due to causes other than rectal cancer

	Category^a	Censored n = 131	Died of non-RC n = 50	Recurred n = 157	Bivariate hazard ratio (95% CI)	Wald P
Adjuvant chemotherapy	No	30	37	63	REF	0.830
Adjuvant chemotherapy	Yes	101	13	94	0.97 (0.70–1.33)	0.830
Year of resection	1995–1999	17	14	48	0.92 (0.80–1.05)	0.206
	2000–2004	29	20	34
	2005–2009	34	10	39
	2010–2014	20	4	21
	2015–2019	31	2	15
Age	< 75 years	117	24	126	REF	0.501
Age	≥ 75 years	14	26	31	0.87 (0.59–1.30)	0.501
Peripheral vascular disease	No	130	45	147	REF	0.259
Peripheral vascular disease	Yes	1	5	10	1.39 (0.78–2.48)	0.259
Intra-abdominal or pelvic abscess/haematoma	No	119	45	147	REF	0.336
Intra-abdominal or pelvic abscess/haematoma	Yes	12	5	10	0.73 (0.39–1.38)	0.336

Italicized P values indicate P significance at ≤ 0.05
RC rectal cancer, CI confidence interval
^aIn each cell, first line is the reference category coded 0, second line is the category of interest coded 1

ISSN: 1477-7819